Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

upplemental oxygen, which increases their risk of developing BPD. Discovery believes that after an initial RDS treatment, BPD may be successfully treated with repeated doses of a non-immunogenic, precision-engineered synthetic surfactant (Surfaxin) to improve the clinical outcome of these infants.

Discovery's Proprietary KL-4 Surfactant Technology: Product Candidates Surfaxin(r) and Aerosurf(tm)

Discovery's surfactant product candidates, including Surfaxin and Aerosurf, are engineered versions of natural human lung surfactant and contain the precision-engineered KL-4 peptide. KL-4 is a 21 amino acid protein-like substance that is designed to closely mimic the essential attributes of human surfactant protein B (SP-B), the surfactant protein most important for the proper functioning of the respiratory system. KL-4 surfactant has the potential to be precisely formulated, either as a liquid instillate, aerosolized liquid or dry powder, to address various respiratory diseases affecting premature infants, children and adults.

Surfaxin, a precision-engineered Surfactant Replacement Therapy (SRT) administered as a liquid-instillate, represents a potential alternative to animal-derived surfactants. Surfaxin's precision-engineered and non-immunogenic nature allows it to be further developed as a therapeutic to address other pulmonary conditions in neonatal and pediatric medicine. Data from Discovery's pivotal, multinational SELECT study demonstrate that Surfaxin is significantly more effective in the prevention of RDS and results in improved survival (continuing through at least one year of life) and other outcomes versus comparator surfactants. The SELECT and STAR (a supportive Phase 3 study) trials, as well as a pooled Phase 3 analysis, have been presented at several international medical meetings and the results from the two studies were published in Pediatrics.

Aerosurf is a precision-engineered, aerosolized SRT administered via nasal continuou
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:10/30/2014)... -- Stryker Orthopaedics, the Official Joint Replacement Products of ... its debut year of the relationship at the Charles ... This marks the eleventh tournament stop along both ... has activated on-site with the "Stryker Mobility Zone" – ... importance of joint health.  The Stryker ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Electronic ... dramatically as a result of government initiatives and ... - healthcare providers have invested over the past ... heart of health IT, and U.S. clinicians use ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... United Kingdom , Oct. 30, 2014 ... (Nasdaq: CBRX ) and Maryland ... drug developers with improved efficiency during clinical development that ... Diego next week. This partnership ... technologies platform, which it launched earlier this month. The ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... International Partnership for Microbicides, issued the following statement ... and effectiveness study of BufferGel and PRO2000 (0.5 ... Microbicide Trials Network, a worldwide collaborative group funded ... released final results from its Phase II/IIb safety ...
... Only Approved Platelet Producer in Europe Represents New ... Feb. 6 Amgen (Nasdaq: AMGN ... has granted marketing authorisation for Nplate(R) (romiplostim) for ... thrombocytopenic purpura (ITP) patients who are refractory to ...
Cached Medicine Technology:New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 2New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 3New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8
(Date:10/30/2014)... 2014 Five months after their expansion, ... LLC announces new branding and a website to accompany ... After David Mepham’s promotion to name partner earlier this ... to include Mepham’s name and better reflect their combined ... firm, the decision to implement new branding reflects Hodgkinson ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. ... have been identified that appear linked to autism spectrum ... they are on their way to discovering up to ... Autism spectrum disorders include a range of developmental ... behaviors. An estimated one in 68 U.S. children has ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Global prebiotics ... 2020, according to a new study by Grand View ... surging demand for sugar and fat free products owing ... the demand for prebiotics over the forecast period. , ... , Food & beverage was the largest application ...
(Date:10/30/2014)... TX (PRWEB) October 30, 2014 ... released today its 2014 third quarter infection rates ... Texas boasted infection rates of only two percent ... patient satisfaction scores exceeding 98 percent. , “We ... quarter, which included rising satisfaction scores,” said Robert ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... milk could be bad for your health, a new study ... milk can help strengthen bones and prevent osteoporosis. These benefits ... milk as part of a healthy diet. But this ... not protect men or women from bone fractures, and was ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... (vitamin C) or its close relative, erythorbate, and the reduced ... have been accompanied by a steep drop in the death ... 10th AACR International Conference on Frontiers in Cancer Prevention Research, ... for colon cancer has apparently not changed much since 1978, ...
... Women living in rural areas face unique challenges concerning health ... rural women are more likely than women living in cities ... form of the disease. "The stage at which the ... of treatment, recovery and survivability," said Faustine Williams, a doctoral ...
... , MONDAY, Oct. 24 (HealthDay News) -- Yoga instruction ... discomfort from chronic moderate lower-back pain, new research suggests. ... pain on your own by following the exercise, lifestyle ... found. "For a person with garden-variety back pain ...
... MONDAY, Oct. 24 (HealthDay News) -- For the millions of ... taking the pills at bedtime may be best. It ... of the day can affect patients, blood pressure patterns, but ... study included 661 patients with chronic kidney disease and hypertension. ...
... breast cancer survival rates found that the probability that a ... death because of screening mammography may be lower than previously ... Archives of Internal Medicine , one of the JAMA/Archives journals. ... survivor than ever before," the authors write. "Between 1971 and ...
... HealthDay Reporter , MONDAY, Oct. 24 (HealthDay News) -- ... (BPA) while in their mother,s womb may be more likely ... new research finds. BPA is a chemical widely used ... mothers gave urine samples that were tested for BPA while ...
Cached Medicine News:Health News:Could additives in hot dogs affect incidence of colon cancer? 2Health News:Rural women more likely to be diagnosed with most serious form of breast cancer 2Health News:Yoga, Stretching Classes Outdo Self-Care for Back Pain: Study 2Health News:Yoga, Stretching Classes Outdo Self-Care for Back Pain: Study 3Health News:Taking Blood Pressure Meds at Bedtime May Be Better 2Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 2Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 3Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 4Health News:BPA Exposure in Womb Linked to Behavioral Woes in Girls 2Health News:BPA Exposure in Womb Linked to Behavioral Woes in Girls 3
... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
Medicine Products: